Galvanize Therapeutics® Launches Initial Commercial Procedures with the New Aliya® EX System

On August 11, 2026, Galvanize Therapeutics announced the first commercial procedures carried out using its new Aliya® EX System, which represents an important milestone in the commercialization of its pulsed electric field technology. These procedures involved both percutaneous and endoscopic methods, showing the system's potential for use in a wider range of interventional applications. Aliya® EX can achieve up to twice the ablation diameter and up to seven times the ablation volume compared to the previous-generation system, while still providing non-thermal energy delivery.

The company states that the system may allow physicians to consider treating more patients with pulsed electric field ablation by joining biopsy and ablation within standard workflows. The technology is intended for the surgical ablation of soft tissue and is currently approved for use in the United States. The commercial launch could thus help promote greater acceptance of advanced minimally invasive ablation technologies. Still, any potential immune-response benefits remain under investigation and have not been proven to benefit patients.

Impact on the Medical Devices Sector

The global medical devices market size is valued at USD 678.88 billion in 2025 and is projected to increase from USD 719.61 billion in 2026 to approximately USD 1,209.42 billion by 2035, expanding at a CAGR of 5.94% from 2026 to 2035.

According to Precedence Research, the introduction of the Aliya® EX could increase competition in the market for soft-tissue ablation devices by showing that pulsed electric field technology has been commercially adopted in both percutaneous and endoscopic procedures. Since it is capable of offering up to twice the ablation diameter and seven times the ablation volume, it could allow physicians to treat a wider variety of lesions with the medical device.

This achievement might lead other medical-device manufacturers to put extra target into non-thermal ablation technologies, workflow integration, and larger treatment areas. The necessity for training, reimbursement arrangements, procedural efficiency, and comparative evidence that proves clear benefits over existing treatment technologies. Additionally, future acceptance will depend on clinical results and the level of physician experience.

Impact on Oncology Sector

The global oncology market size was calculated at USD 250.88 billion in 2025 and is predicted to increase from USD 279.73 billion in 2026 to approximately USD 732.45 billion by 2035, expanding at a CAGR of 11.31% from 2026 to 2035.

According to Precedence Research, patient demand for more efficient treatment pathways is rising. For oncology, this development could offer a slight expansion of the range of minimally invasive treatments available to patients who need soft-tissue tumor ablation, especially in cases where percutaneous or endoscopic access is clinically appropriate. A more extensive ablation area may enable doctors to treat lesions beyond the capabilities of earlier-generation pulsed electric field devices.

This launch enables commercial use; it should not be taken as evidence that it improves cancer survival or provides any immune-mediated therapeutic benefit. The extent to which it will have an impact in the field of oncology will depend on the results of prospective clinical studies. The initiative applied to durable local-control data, safety outcomes, patient selection, and comparisons with existing ablation and surgical treatment infrastructure.

Impact on the Endoscopy Devices Sector

The global endoscopy devices market size is calculated at USD 60.51 billion in 2025 and is predicted to increase from USD 64.80 billion in 2026 to approximately USD 118.22 billion by 2035, growing at a CAGR of 6.93% from 2026 to 2035.

According to Precedence Research, Healthcare providers might now have the chance to include pulsed electric field ablation in their interventional programs, especially since Aliya® EX offers both percutaneous and endoscopic methods of delivery. The first commercial endoscopic procedure shows that there could be relevance for use in interventional pulmonology, a field where minimally invasive access is important for pulmonary lesions.

Wider acceptance will depend on physicians and hospitals assessing the requirements relating to procedural training, the cost of equipment, patient selection, reimbursement, and integration with current imaging and treatment systems. With the rising need for clinical records, pulsed electric field technology could then become a more firmly established part of multidisciplinary soft-tissue intervention and procedural oncology programs.

Expert Opinion

From an expert point of view, the most important point about this announcement is not just that it marks the first commercial application, but that Aliya®  EX is moving from having received regulatory approval towards being adopted in a clinical setting. Its greater treatment capacity may overcome one of the key limitations of earlier-generation ablation systems and could thus improve the flexibility of the procedure in the commercial sector by providing clinical evidence.

The percutaneous and endoscopic methods have been demonstrated to increase the platform's relevance across a range of interventional specialties. The technology's true value will be determined by its real-world safety, the ability to achieve durable local control, procedural efficiency, reimbursement arrangements, and comparative clinical data. Likewise, any assertions about immune stimulation should remain cautious until prospective studies demonstrate that these effects result in actual benefits for patients.